Circulating tumor cells in breast cancer: applications in personalized medicine.
Breast Cancer Res Treat
; 160(3): 411-424, 2016 12.
Article
em En
| MEDLINE
| ID: mdl-27761678
ABSTRACT
Recent technological advancements in rare cell analysis have facilitated the detection of circulating tumor cells (CTCs) in the blood of patients diagnosed with breast and other types of cancers. Numerous clinical studies involving the enumeration of CTCs in breast cancer patients have unequivocally demonstrated the prognostic value of these cells. Evidence from recent molecular studies indicates that CTCs may be potential surrogate markers for systemic disease. As such, real-time assessment of therapeutic biomarkers in breast CTCs, such as the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2), may have a tremendous impact in guiding-targeted cancer therapy. In this review, we discuss the clinical implications of CTC detection and its potential utility for personalized medicine in breast cancer.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Células Neoplásicas Circulantes
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Breast Cancer Res Treat
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
Estados Unidos